Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones | News Direct

Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones

Immunic Inc
News release by Immunic Inc

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | May 09, 2024 06:58 AM Eastern Daylight Time


Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.

Vitt said the quarter was notable for Immunic's successful fundraising efforts, raising up to $240 million in a three-tranche private placement aimed at furthering its Multiple Sclerosis (MS) and gastrointestinal treatments.

He also highlighted the importance of the recent allowance of a fourth US patent for vidofludimus calcium, enhancing its intellectual property portfolio around MS treatments and ensuring long-term commercial exclusivity.

Vitt gave an update on the status of ongoing clinical trials, including the advanced Phase 2 CALLIPER trial for MS, with significant results expected in April next year.

Moreover, he touched on Immunic's gastrointestinal disorder programs, particularly for celiac disease, with the IMU-856 program showing promising results in restoring gut wall functions.

The interview also covered upcoming milestones, focusing on executing current clinical trials and preparing for future phases.


Contact Details


Proactive North America


+1 604-688-8158

project media


HealthBiotechPharmaDrug developmentClinical trialsAutoimmune diseaseSmall Molecule Therapy